TheranosticTrials.org

Clinical Trial · NCT04487847

18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

Overview

To study the added value of 18F-PSMA-1007 PET to mpMRI in the detection of local prostate cancer lesions.

Sponsor

Radboud University Medical Center

Phase

Phase 1/2

ClinicalTrials.gov

NCT04487847

Drug / Compound

PSMA-1007

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Linker: 6-fluoronicotinamide prosthetic group / naphthalene-based linker region

Eligibility

Inclusion

  • Males ≥ 18 years
  • ECOG 0-1
  • Suspicion for PCa (e.g. elevated PSA, suspicious rectal examination)

Exclusion

  • History of prostate cancer
  • Any medical condition that in the opinion of the investigator will affect patients' clinical status when participating in this trial.
  • Any prior surgery in the pelvic area that might interfere with the scans (e.g. hip replacement surgery)
  • Second active malignancy
  • Contra-indications for mpMRI or PET: claustrophobia or inability to lay still for the duration of the exam.
  • Prostate biopsy in the last 6 months